New hope for IBD patients: switching to guselkumab after ustekinumab fails
Disease control
Recruiting now
This study looks at whether switching to a drug called guselkumab (Tremfya) can help people with inflammatory bowel disease (IBD) who did not get enough relief from ustekinumab. About 200 adults across Canada will take guselkumab for one year, and doctors will track their symptom…
Sponsor: TIDHI Innovation Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC